Primary Biliary Cholangitis (PBC)
Conditions
Brief summary
A phase II study to evaluate safety, tolerability and efficacy of CS0159 in patients with PBC (Primary Biliary Cholangitis).
Detailed description
This is a phase II study to evaluate safety, tolerability and efficacy of CS0159 in patients with PBC (Primary Biliary Cholangitis). The study has been designed to have two parts, the first part of the study will be double-blinded for 12 weeks. The second part of the study will be an open-label trail lasting 40 weeks.
Interventions
DRUG2mg CS0159
Oral QD
DRUGPlacebo
Oral QD
Sponsors
Cascade Pharmaceuticals, Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. When signing ICF age≥18 years≤75 years, male or female 2. Meets the diagnostic criteria of PBC, such as elevation ALP, positive AMA or AMA-M2, If negative for AMA, positive for PBC specific antibody and Liver biopsy meeting PBC criteria six months before screening 3. 1.67 × ULN ≤ALP ≤ 10 × ULN and TBil≤ 3 × ULN 4. UDCA≥6 months before randomization and a stable dose (no less than 13-15 mg/kg/d in principle) ≥3 months after the efficacy was poor (meeting inclusion criteria 3), or UDCA was not tolerated, and stop taking UDCA (no UDCA use for ≥3 months before randomization) 5. Understand the study content, comply with the study protocol, and sign the ICF voluntarily \-
Exclusion criteria
1. ALT or AST\>5×ULN； 2. OCA(Obercholic acid) in the 3 months prior to randomization 3. Known concomitant hepatobiliary disease or history 4. Significant hepatic impairment as defined by Child-Pugh classification of B or C, history of liver transplantation, current placement on a liver transplant list or current Model for End Stage Liver Disease (MELD) score ≥15. 5. Patients were screened for HBsAg positive, HCVAb positive, HIV Ab positive, or TPAb positive. 6. (creatinine, Cr) ≥1.5×ULN and Cr clearance rate \<60 mL/min 7. Platelet\<80×10\^9/L； 8. INR\>1.3 9. ALB\<3.5 g/dL 10. Severe pruritus or systemic medication was required within 2 months prior to randomization 11. Arrhythmia, Or during screening the QTc interval was ≥450 ms for male and 470 ms for female 12. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the large intestine, eg, inflammatory bowel disease, prior or planned (during the study period) bariatric surgery (such as gastroplasty, roux-en-Y gastric bypass). 13. Concomitant use of medications, food, and drinks that are strong or moderate CYP3A4 inhibitors or inducers within 14 days prior to the first dose of study drug and throughout the study duration. 14. Diseases that may cause non-hepatic elevation of ALP (such as Paget's disease) or may result in a life expectancy of less than 2 years 15. A history of malignant tumor within 5 years prior to randomization 16. Perazathioprine, colchicine, cyclosporine, methotrexate, mycophenolate, and pentoxifylline were administered from 28 days before randomization to the entire clinical study period. Fenofibrate or other Bates; Budesonide and other systemic corticosteroid hormones; Hepatotoxic drugs; Liver protection Drugs and other hepatoprotective drugs were given a stable dose \<28 days before randomization or could not be maintained during the trial; cholagogue 17. The administration of interleukin or other cytokine antibodies, as well as chemical factors or immunotherapy, was prohibited from 12 months prior to randomization throughout the clinical study period 18. Substance abuse or alcoholism from 6 months prior to randomization throughout the entire clinical study period 19. Poor blood pressure control is indicated by a systolic pressure greater than 160 mmHg or diastolic pressure greater than 100 mmHg during screening 20. Poor blood glucose control, that is, HBA1c \>9.0% at screening 21. Pregnancy, planned pregnancy, lactation 22. Use of other investigational drugs within 3 months 23. Any other condition(s) that would compromise the safety of the patient or compromise the quality of the clinical study, as judged by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AE incidence | baseline to 12 weeks | AE incidence in three arms |
| relative changes from baseline in ALP at week 12 | baseline to 12 weeks | Compared with placebo ,Percentage change of CS0159 to ALP relative to baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Absulute changes from baseline in ALP at week 12 | baseline to 12 weeks | Compared with placebo, CS0159 changes in serum ALP relative to baseline |
| ALP and TBil | baseline to 12 weeks | Compared with placebo, the rate of subjects to achive the lelve of ALP\< 1.67 ULN and (total bilirubin) TBil ≤ULN |
| Pruritus | from basline to 40 weeks | the changes from baseline in Pruritus to week 40 |
| Liver function: ALT, AST, ALB, LDL-C, HDL-C, TBA, GGT, TC, TG | from baseline to week 40. | The reduction of ALT, AST, ALB, LDL-C, HDL-C, TBA, GGT, TC, and TG from baseline to week 40. |
Countries
China
Contacts
STUDY_DIRECTORRong Deng
Cascade Pharmaceuticals, Inc
Outcome results
None listed